Advair

Novartis Smoker’s Cough Treatment Beats Glaxo’s Advair in Trial

Novartis Smoker’s Cough Treatment Beats Glaxo’s Advair in Trial

Bloomberg Businessweek

GSK and Theravance file next-generation Advair in USA, EU

GSK and Theravance file next-generation Advair in USA, EU

Pharma Times, UK

Glaxo Executives Cited in Case Now Lead Sanofi, Actelion

Glaxo Executives Cited in Case Now Lead Sanofi, Actelion

Bloomberg Businessweek

Breathe Easy: Relovair Program Complete, Data Solid

Breathe Easy: Relovair Program Complete, Data Solid

Motley Fool

Theravance: A $1.5 Billion Company With An $8 Billion Product

Theravance: A $1.5 Billion Company With An $8 Billion Product

Seeking Alpha

Glaxo Tests Cheaper Version of Advair for Emerging Markets

Glaxo Tests Cheaper Version of Advair for Emerging Markets

Bloomberg

Lipitor's $131B lifetime sales dwarf other megablockbusters

Lipitor's $131B lifetime sales dwarf other megablockbusters

Fierce Pharma

Vectura gets new U.S. partner for copy of lung drug

Vectura gets new U.S. partner for copy of lung drug

Reuters

As Advair Sales Erode, Benlysta Gets EMA Nod

As Advair Sales Erode, Benlysta Gets EMA Nod

Motley Fool

News

GSK chief was right about tough-to-copy Advair

Fierce Pharma